PSNL News and Press, Personalis Inc. From 02/08/21

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced the appointment of Susan Moriconi as VP of People and Chief Human Resources Officer. Ms. Moriconi joins Personalis from Omnicell, Inc. (Nasdaq: OMCL), where she most ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Thursday, February 18, 2021 at 12:00 p.m. Eastern Time. Abo...

Exact Sciences (EXAS), Natera (NTRA), Personalis (PSNL), and Veracyte (VCYT) are all trading sharply higher today, as Truist Securities initiates coverage with buy recommendations on the stocks.With a price target of $65 and ~21.4% of upside to the previous close, the only laggard in the list...

Shares of Personalis (NASDAQ: PSNL) are down by 12.1% as of 3:48 p.m. EST on Wednesday, after dropping by as much as 15.1%. Investors are selling off the company's stock following its announcement of the pricing of a public offering of common stock. Personalis has been on fire on th...

Personalis (PSNL) has priced its public offering of 3.95M common shares at $38.00/share, for expected gross proceeds of $150.1M. Underwriters' over-allotment is an additional 592.5K shares.Previously (Jan. 26): Personalis trades in red after launching $150M in underwritten public offering F...

Personalis (PSNL) slumped 3.6% in after hours trade after commencing an underwritten public offering of $150M; underwriters granted 30-day option to purchase up to an additional $22.5 M of common stock.Offer size, terms have not yet been disclosed. For further details see: Per...

A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions. A look back at companies I have written articles about over the last three years - 2018-2020. The good, the bad and the ugly! For further details see: Fin...

With so much hype around coronavirus vaccine stocks, it was easy to miss Personalis (NASDAQ: PSNL) , which became a 10-bagger after the market crash last year. Personalis is a biotech that competes with Guardant Health (NASDAQ: GH) and Adaptive Biotechnologies (NASDAQ:...

Personalis (PSNL) reports Q4 preliminary revenue of ~20.2M, vs $18.2M previously, representing an increase of 11%. For the FY 2020, revenue is estimated to be ~$78.6M compared with $65.2M for 2019, representing an increase of 21%.Preliminary revenue from biopharma and all other...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2020. Personalis estimates revenue of approximately $20.2 million for the fourth ...